Gastrointestinal ReProgramming (GaRP) complementary medicine
Anatara is seeking to partner with international pharmaceutical and consumer health companies for the commercialisation of its Gastrointestinal ReProgramming (GaRP) dietary supplement product which has been designed to address the primary underlying factors associated with human gastrointestinal conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet need and market opportunity. In February 2019, Anatara announced breakthrough positive efficacy data from its in vitro Proof of Concept studies of its GaRP dietary supplement product in both reducing inflammation and restoring gut integrity. Further information can be found here. With preclinical development successfully completed (further information can be found here), recruitment for a clinical trial in subjects with IBS-D commenced in August 2021.
3FDC (3 components with functional delivery coating) complementary medicine
3FDC has been designed so coated components are released in the large intestine (colon) to positively influence the gut-brain connection, targeting modulation of psychobiological processes driving anxiety-related disorders and to assist homeostasis of the “gut” to promote overall health and wellbeing. The formulation combines synergistic, generally regarded as safe (GRAS) ingredients. A psychological functioning trial of 3FDC commenced in mid-February 2022 in subjects with moderate levels of depression, anxiety, or stress symptoms indicated by the Depression, Anxiety and Stress Scale (DASS-21).
Non-antibiotic formulations for pigs and poultry
Anatara developed Detach® for the control of scour (diarrhoea) in pigs which was approved the Australian Pesticides and Veterinary Medicines Authority (APVMA) for this application.
Detach® has been shown to reduce post-weaning diarrhoea and provide similar protection to antimicrobial agents including zinc oxide as well as reduce antimicrobial resistance However, Detach® requires labour and effort to deliver the compound by drenching. BONIFF is a revised formulation that is applied to dry feed for piglets after weaning, reducing labour input and simplifying the entire process. Anatara successfully completed a piglet challenge trial which concluded that BONIFF could be considered as a replacement for a non-physiological level of zinc oxide with commercial levels of additives in a semi-moist extruded creep piglet diet.
Anatara has also developed ANR-pf, a proprietary enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method on-farm even when stock illness is a concern. Anatara successfully completed a poultry challenge trial “Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges”.
Further information about Anatara’s animal health solutions can be found here.
Anatara is seeking interest from international animal health companies in licensing Detach® or BONIFF for use in pigs, or ANR-pf for use in poultry, in Australia and/or overseas markets.
Anatara is exploring partnering opportunities for the licencing of Detach®, BONIFF, ANR-pf and/or GaRP for use in companion animals. Gastrointestinal issues remains a common health concern in dogs and cats.
To discuss opportunities to partner with Anatara on our programs, please contact:
John Michailidis, Chief Operating Officer
M: +61 418 337 377